Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

A Forbes, A Al-Damluji, S Ashworth, M Bramble, K Herbert, J Ho, J-Y Kang, R Przemioslo, A Shetty

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR.
Original languageEnglish
Pages (from-to)1099-1104
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Issue number9
Publication statusPublished - 1 May 2005


  • Anti-Inflammatory Agents, Non-Steroidal
  • Colitis, Ulcerative
  • Female
  • Humans
  • Male
  • Mesalamine
  • Middle Aged
  • Tablets, Enteric-Coated
  • Treatment Outcome

Cite this